Cosmo Bio Company,Limited
Cosmo Bio Earnings Guidance Revision | July 2026
Cosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (up 0.9% vs. previous forecast) and net income attributable to shareholders of 320 million yen (up 45.5% vs. previous forecast), expecting increased profit driven by yen depreciation and gains from the sale of investment securities.
Key Figures
- Net sales: 11,500 million yen (up 0.9% vs. previous forecast)
- Net income attributable to shareholders: 320 million yen (up 45.5% vs. previous forecast)
- Full-year forecast operating income: 270 million yen (flat)
AI要約
Summary of Financial Results
Cosmo Bio has revised its full-year earnings forecast for the fiscal year ending December 2026 to net sales of 11,500 million yen (an increase of 100 million yen from the previous forecast) and net income attributable to shareholders of 320 million yen (an increase of 100 million yen from the previous forecast). The increase in sales is driven by steady overseas markets and impacts from yen depreciation, along with gains from the sale of investment securities. Despite considering increased costs and exchange rate fluctuations, the Company continues proactive investments with an outlook for profit growth.
Future Outlook and Shareholder Impact
The depreciating yen and strong overseas sales have led to upward revisions of the full-year sales and net profit forecasts. Particularly, net income has increased by 45.5%, indicating a significant improvement and providing a positive outlook for shareholder returns and future investment activities. The Company plans to continue expanding its global presence and new businesses to strengthen its revenue base.
Cosmo Bio Co., Ltd.
Company overview · Stock price · Financial data · All IR
